Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles

International Journal of Pharmaceutics

Volumn 341, Issue 1-2, 2007, Pages 207-214

  Dreis, S ^a   Rothweiler, F ^b   Michaelis, M ^b   Cinatl Jr , J ^b   Kreuter, J ^a   Langer, K ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cell viability; Doxorubicin; Human serum albumin (HSA); Nanoparticles; Physicochemical characterisation

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; NANOPARTICLE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; NEUROBLASTOMA CELL; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

ADSORPTION; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INHIBITORY CONCENTRATION 50; NANOPARTICLES; NEUROBLASTOMA; PARTICLE SIZE; SERUM ALBUMIN; TECHNOLOGY, PHARMACEUTICAL;

EID: 34447623755     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.03.036     Document Type: Article

References (34)

1. Ambruosi A., Khalansky A.S., Yamamoto H., Gelperina S.E., Begley D.J., and Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 14 (2006) 97-105
2. Barraud L., Merle P., Soma E., Lefrancois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trepo C., and Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42 (2005) 736-743
3. Carter D.C., and Ho J.X. Structure of serum albumin. Adv. Protein Chem. 45 (1994) 153-203
4. Cinatl J., Cinatl J., Mainke M., Weissflog A., Steigmann G., Rabenau H., Doerr H.W., and Kornhuber B. Aphidicolin selectively kills neuroblastoma cells in vitro. Cancer Lett. 67 (1992) 199-206
5. Configliacchi E., Razzano G., Rizzo V., and Vigevani A. HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates. J. Pharm. Biomed. Anal. 15 (1996) 123-129
6. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., and Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44 (1992) 509-517
7. Damascelli B., Cantu G., Mattavelli F., Tamplenizza P., Bidoli P., Leo E., Dosio F., Cerrotta A.M., Di Tolla G., Frigerio L.F., Garbagnati F., Lanocita R., Marchiano A., Patelli G., Spreafico C., Ticha V., Vespro V., and Zunino F. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92 (2001) 2592-2602
8. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
9. Duncan R., Vicent M.J., Greco F., and Nicholson R.I. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer. 12 (2005) S189-S199
10. Eatock M., Church N., Harris R., Angerson W., McArdle C., French R., and Twelves C. Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule. Invest. New Drugs 17 (1999) 111-120
11. Feinstein S.B., Cheirif J., Ten Cate F.J., Silverman P.R., Heidenreich P.A., Dick C., Desir R.M., Armstrong W.F., Quinones M.A., and Shah P.M. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J. Am. Coll. Cardiol. 16 (1990) 316-324
12. Geny B., Mettauer B., Muan B., Bischoff P., Epailly E., Piquard F., Eisenmann B., and Haberey P. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J. Am. Coll. Cardiol. 22 (1993) 1193-1198
13. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
14. Hurwitz E., Levy R., Maron R., Wilchek M., Arnon R., and Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 35 (1975) 1175-1181
15. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., and Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8 (2002) 1038-1044
16. Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., Schumacher P., Falken U., and Unger C. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin. Biol. Pharm. Bull. 21 (1998) 56-61
17. Kratz F., Beyer U., Roth T., Tarasova N., Collery P., Lechenault F., Cazabat A., Schumacher P., Unger C., and Falken U. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87 (1998) 338-346
18. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257 (2003) 169-180
19. Leo E., Cameroni R., and Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int. J. Pharm. 180 (1999) 23-30
20. Leo E., Vandelli M.A., Cameroni R., and Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking process. Int. J. Pharm. 155 (1997) 75-82
21. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 65 (2000) 271-284
22. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
24. Neault J.F., and Tajmir-Riahi H.A. Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim. Biophys. Acta 1384 (1998) 153-159
25. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., and Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53 (1993) 4238-4242
26. Purcell M., Neault J.F., and Tajmir-Riahi H.A. Interaction of taxol with human serum albumin. Biochim. Biophys. Acta 1478 (2000) 61-68
27. Seymour L.W., Ulbrich K., Strohalm J., Kopecek J., and Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39 (1990) 1125-1131
28. Singal P.K., Li T., Kumar D., Danelisen I., and Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell Biochem. 207 (2000) 77-86
29. Smith P. Measurement of protein using bicinchiconic acid. Anal. Biochem. 150 (1995) 76-85
30. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
31. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., and Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 12 (2004) 461-471
32. Wartlick H., Spänkuch-Schmitt B., Strebhardt K., Kreuter J., and Langer K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Rel. 96 (2004) 483-495
33. Weber C., Kreuter J., and Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int. J. Pharm. 196 (2000) 197-200
34. Yoo H.S., Oh J.E., Lee K.H., and Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16 (1999) 1114-1118